Status:
NOT_YET_RECRUITING
Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
Lead Sponsor:
Seoul National University Hospital
Conditions:
Breast Cancer
Post-Operative Hematoma
Eligibility:
FEMALE
20-70 years
Brief Summary
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory dru...
Eligibility Criteria
Inclusion
- Systemic performance status 0-2 according to ECOG criteria
- Patients with adequate renal function: serum Cr 1.4 mg/dL or less
- Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal
- Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)
- Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)
- Patients who voluntarily decided to participate in this study and signed a written informed consent form
Exclusion
- Patients undergoing immediate reconstruction operation
- Patients with drug allergies to painkillers and anti-inflammatory drugs
- Patients with a physical condition that would interfere with understanding and submitting the consent form
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 20 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06575049
Start Date
May 1 2025
End Date
February 20 2026
Last Update
September 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.